Amgen and Takeda announced motesanib advanced lung cancer study failed
Amgen and Takeda recently announced late in advanced lung cancer patients in clinical studies of a drug candidate motesanib does not improve overall survival of patients. The study by 1090 with advanced non-squamous non-small cell lung cancer patients to participate in Phase Ⅲ clinical study did not meet key clinical endpoint goal.
Amgen and Takeda announced motesanib advanced lung cancer study failed
ReplyDeleteAmgen and Takeda recently announced late in advanced lung cancer patients in clinical studies of a drug candidate motesanib does not improve overall survival of patients. The study by 1090 with advanced non-squamous non-small cell lung cancer patients to participate in Phase Ⅲ clinical study did not meet key clinical endpoint goal.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Panobinostat
Belinostat
PCI-24781
Entinostat
Mocetinostat
AR-42
Droxinostat
Pracinostat
Trichostatin A
ARN-509